BioSpace News Archive

BioStem Technologies is commending the U.S. Department of Health and Human Services Office of Inspector General’s (HHS OIG) recent recommendation for the Centers for Medicare and Medicaid Services (CMS) to quickly address issues associated with Average Sales Price (ASP) reporting requirements for skin substitute products.

Cognition Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Monte Rosa Therapeutics, Inc. today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors.

Dyne Therapeutics, Inc. today announced that DYNE-251 was granted U.S. Food and Drug Administration (FDA) orphan drug and rare pediatric disease designations.

Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration’s (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.

Enveric Biosciences, Inc. today announced that it has entered into an agreement with Avance Clinical for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeting the treatment of anxiety disorders.

Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming investor conferences.

Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.

Coya Therapeutics, Inc. today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET.

Evaxion Biotech A/S today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.